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Aims To localize chromosomal regions (or quantitative trait loci) that harbour genetic variants influencing the variability of
electrocardiographic (ECG) and echocardiographic left ventricular hypertrophy (LVH).
Methods
and results
We evaluated genetic linkage to ECG Sokolow-Lyon voltage, ECG Cornell voltage product, ECG left ventricular (LV)
mass, and to echocardiographic septal wall thickness, LV cavity size, and LV mass in 868 members of 224 white British
families. A genome-wide scan was performed with microsatellite markers that covered the genome at 10-cM intervals
and linkage was assessed by variance components analysis. We identified chromosomal regions suggestive of linkage
for Sokolow-Lyon voltage on chromosome 10q23.1 [log10 of the odds (LOD ¼ 2.21, P ¼ 0.0007)], for ECG Cornell
voltage product on chromosome 17p13.3 (LOD ¼ 2.67; P ¼ 0.0002), and for ECG LV mass on chromosome 12q14.1
(LOD ¼ 2.19; P ¼ 0.0007). There was a single region of possible linkage for echocardiographic LV mass on chromo-
some 5p14.1 (LOD ¼ 1.6; P ¼ 0.003).
Conclusion Stronger genetic signals for LVH were found using electrocardiographic than echocardiographic measurements, and
the genetic determinants of each of these appear to be distinct. Chromosomes 10, 12, and 17 are likely to harbour
genetic loci that exert a major influence on electrocardiographic LVH.
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Introduction
Left ventricular hypertrophy (LVH) measured by the electrocar-
diogram (ECG) or the echocardiogram (echo) is a major risk
factor for cardiovascular morbidity and mortality.1,2 Whereas
LVH is a multifactorial trait that is influenced by blood pressure
(BP), body size, and gender, there is increasing evidence showing
that genetic factors influence the inter-individual variation in this
trait.3–11 The specific genetic loci that influence naturally occurring
variation in LVH, however, remain largely unknown.12 The inser-
tion/deletion polymorphism in intron 16 of the angiotensin-
converting enzyme (ACE) gene was the first polymorphism to
be implicated in LVH,13 but subsequent investigations of this
association have produced conflicting results.14 Numerous other
candidate gene studies, conducted in the general population and
in people with hypertension, have revealed either the absence of
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an association or the presence of an association only in particular
subgroups.15
We have conducted a whole genome linkage analysis in families
with hypertension to identify novel quantitative trait loci that influ-
ence electrocardiographic and echocardiographic LVH. We have
studied families who were selected through a hypertensive
proband, resulting in a high prevalence of ECG-LVH and echo-LVH
of 10% and 34%, respectively.5 In contrast with previous studies
that have analysed echocardiographic LVH,16 we have extended
our analysis to include electrocardiographic measures of LVH,
which we have previously shown to be heritable.5 This study thus
provides the most comprehensive analysis of this question to date.
Methods
Study participants
Two hundred and forty-eight white British families, comprising 1428
individuals, were recruited in Oxfordshire between 1993 and 1997
as previously described.17 Briefly, families were selected through a
hypertensive proband with documented systolic and diastolic BP in
the top 5% of the population distribution either on multiple clinical
readings or ambulatory BP monitoring. In order to be suitable for
the study, families were required to consist of at least three siblings
(including the proband) clinically assessable for BP if at least one
parent of the sibship was available to give blood for DNA analysis,
and to consist of at least four assessable siblings (including the
proband) if no parent was available for DNA analysis. Qualifying sib-
ships could be either in the generation of the proband or his/her off-
spring, and there was no requirement for the sibship to contain
additional members affected with hypertension (though this was not
an exclusion criterion). Where members of the sibship were found
to be hypertensive (using identical criteria to those applied in the pro-
bands), families were extended and the spouses and offspring of hyper-
tensive sibs collected. Thus, the family collection includes some
extended families, though most are nuclear families.
Electrocardiographic and echocardiographic measurements were
performed in participants undergoing their second examination cycle
(1998–2001), as previously described.5 The study complies with the
Declaration of Helsinki, the Central Oxford Ethics Committee
approved the protocol, and each participant gave written informed
consent.
Electrocardiography and echocardiography
Resting 12-lead ECGs were obtained from all participants as previously
described in detail.5 The following electrocardiographic measures of
LVH were calculated according to standard recommendations:
Sokolow-Lyon voltage, Cornell voltage, Cornell voltage product, and
electrocardiographic left ventricular (LV) mass in grams [calculated
according to the following formula: 0.026  (RaVL þ SV3) þ 1.25 
weight þ 34.4 for men, and 0.020  (RaVL þ SV3) þ 1.12 
weight þ 36.2 for women].18 Two-dimensional, M-mode, and
Doppler echocardiography was performed according to American
Society of Echocardiography guidelines, as previously described in
this population.5 Echocardiographic measurements used in the
genetic analyses were septal wall thickness in diastole, LV internal
dimension in diastole, and LV mass (calculated according to the
formula of Devereux et al.);19 these traits were chosen because they
are known to be heritable in this family study.5 As previously
described, these measurements were demonstrated to be reproduci-
ble both between-reader and within-subject.5
Genotyping
DNA was extracted from whole blood or buffy coat specimens by a
standard protocol. The 400 microsatellite markers comprising ABI
PRISM linkage marker set MD-10, which span the genome with
approximately 10-cM density and mean heterozygosity 0.79, were
typed by polymerase chain reaction (PCR) and allele separation on
ABI 377 sequencers using publicly available protocols (www.cng.fr).
A CEPH reference individual was included on all genotyping runs to
ensure consistency of allele binning across runs. Mendelian inconsisten-
cies were detected and eliminated with PedCheck.20
Statistical analyses
Regression analysis was used to derive sex-specific standardized
residuals for LVH variables, adjusted for major covariates with SPSS
as previously described.5 Age, systolic BP, weight, and waist-hip ratio
were significant covariates for both ECG and echocardiographic
measures of LV mass; height was a significant covariate for ECG
measures of LV mass; and diabetes was a significant covariate for echo-
cardiographic LV mass. The standardized residuals from the regression
conformed to a normal distribution (P. 0.05). A genome-wide linkage
analysis using these residuals as continuous traits was performed by a
variance components approach implemented in MERLIN.21
Briefly, the variance–components linkage approach involves
the fitting of a linear mixed model to identity-by-descent and quanti-
tative trait data. For each chromosome and pair of relatives,
identity-by-descent probabilities are computed at a regular grid of
genetic locations using multilocus genotypes.21 The mixed model
includes parameters to simultaneously estimate the trait mean with
three components of variance attributable to (1) additive effects
encoded by a quantitative trait locus (QTL), (2) unlinked polygenes,
and (3) random, normally distributed individual-specific effects.22 By
convention, a LOD (log10 of odds ratio) score test is used to summar-
ize the evidence for a linked QTL at each genomic location; this test
compares the general model (with the maximum likelihood estimate
of the QTL variance component) with a nested model (with the
QTL variance component ¼ 0).
Theoretical work based on the availability of complete genetic infor-
mation (i.e. no failed genotypes in typed individuals, complete avail-
ability of parental genotypes, and a high density of genetic markers)
has identified LOD score cut-offs of 2.20 for suggestive evidence of
linkage and 3.63 for significant evidence of linkage in a genome-wide
microsatellite analysis.23 Subsequent work applying a locus counting
approach has however suggested that in most cases LOD scores of
greater than about 1.5 will arise only once by chance in a ‘real
world’ 10 cM-density genome scan with some unavailability of parental
genotyping and a missing data rate of 15%. In such a scenario, LOD
scores of 2.80–2.88 (depending on the availability of parental
data), rather than 3.63, equate to a genome-wide significance level of
P ¼ 0.05.24 We therefore report all loci giving LOD scores  1.5.
Results
The clinical characteristics and mean values for ECG and echocar-
diographic measures of LVH in the 868 participants from 224
families on whom ECG data were available are presented in
Table 1. The median number of individuals with ECG and echo
phenotypes in each family was four, and 168 of 224 families com-
prised between two and six phenotyped and genotyped members.
The median duration of hypertension among those meeting the
study criterion for hypertension was 5.8 years (IQR 2.2–11.6
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years). There was no significant relationship between ECG or echo
LVM and duration of hypertension in regression analyses, therefore
no adjustment for this was made in the linkage analyses. Among the
hypertensives with ECG and echo measurements, 25% were
untreated, 45% were treated with one drug, 25% were treated
with two drugs, and 5% were treated with three or more drugs.
Among the 146 patients taking monotherapy for hypertension,
22% were treated with diuretics, 36% with beta-blockers, 32%
with ACE-inhibitors (ACE-I), and 8% with calcium antagonists.
Analysis of variance showed no significant heterogeneity in either
echo or ECG LV mass between the drug classes in those patients
on monotherapy, therefore no drug-specific adjustments were
made in the linkage analyses.
A summary of LOD scores  1.5 is presented in Table 2. There
were no LOD scores attaining conventional genome-wide levels of
significance on Lander-Kruglyak criteria (LOD .3.63),23 but there
were three regions attaining or approaching suggestive evidence of
linkage for particular measures of LVH (LOD .2.20). There was a
region of suggestive linkage for ECG Sokolow-Lyon voltage on
chromosome 10q23.1 (106.3 cM, LOD ¼ 2.21, P ¼ 0.0007), for
ECG Cornell voltage product on chromosome 17p13.3 (6 cM;
LOD ¼ 2.67; P ¼ 0.0002), and for ECG LV mass on chromosome
12q14.1 (78 cM; LOD ¼ 2.19; P ¼ 0.0007). Of note, this last region
(chromosome 12q14.1) also gave evidence of linkage to the ECG
Cornell voltage product (LOD ¼ 1.73; P ¼ 0.002). There were
two further regions with weaker evidence of linkage for ECG
Cornell voltage product on chromosomes 4 (211.9 cM; LOD
1.68; P ¼ 0.003) and 16 (7.6 cM; LOD ¼ 1.85; P ¼ 0.002). ECG
LV mass showed some evidence of linkage to chromosome 7 at
120 cM (LOD ¼ 1.67; P ¼ 0.003). There was no significant
linkage region for Cornell voltage, echocardiographic septal thick-
ness in diastole or LV internal dimension in diastole. The highest
LOD score for echocardiographic LV mass was on chromosome
5p14.1 at (40.3 cM, LOD ¼ 1.6; P ¼ 0.003).
BP is an important determinant of LVH. ECG and echo pheno-
types were adjusted for systolic BP before genetic analysis, which
should substantially eliminate any BP-mediated effects. However,
since this sample was ascertained on hypertensive probands and
40% of the included individuals were hypertensive, we conducted
additional analyses to specifically address any concern that the lin-
kages we identified were because of genetic effects on BP. We
carried out variance components linkage analysis to BP phenotypes
with the markers showing evidence for linkage to the ECG and
echo phenotypes with an LOD  1.5. First, we tested for linkage
with log-transformed, age- and sex-adjusted systolic, diastolic,
and mean BPs, adjusted for antihypertensive therapy in those on
treatment with addition of 5 mmHg systolic and 2.5 mmHg dias-
tolic pressure per agent taken. Secondly, we conducted linkage
analyses to BP using only those individuals in whom a quantitative
assessment of BP off treatment was available. Finally, we tested for
linkage to hypertension defined qualitatively as in the probands.
There was no significant evidence for linkage to BP at the
markers showing linkage to LVH in any of these analyses (P.
0.1 for all; data not shown).
Discussion
We conducted a whole genome linkage scan for heritable electro-
cardiographic and echocardiographic measures of LVH, and found
that the individual measures yielded distinct regions suggesting
genetic linkage. We obtained four loci with LOD scores for
Cornell voltage product above 1.5, while only one such LOD
score might have been expected by chance alone. Thus, it is
likely that some of the linked regions we describe harbour major
loci influencing the Cornell voltage product. One of these four
markers also gave evidence of linkage (LOD ¼ 2.19) to the trait
of ECG LV mass, which incorporates some overlapping primary
ECG parameters (RaVL þ SV3), but adjusts these by body weight
rather than QRS duration.
There are many ECG indices of LVH, and both the prevalence of
LVH in the population and the relative risk of mortality in those
classified as having LVH, varies depending on which index is
adopted. Hsieh et al. showed that measures of LVH that incorpor-
ate criteria additional to QRS complex size (such as complex dur-
ation in the case of Cornell voltage product) are better predictors
of cardiovascular mortality than criteria based on QRS voltage
alone.25 The regions we have identified that are linked to
Cornell voltage product may therefore be particularly interesting
to examine for association with cardiovascular mortality in pro-
spective studies. Sokolow-Lyon voltage appears to be influenced
to a greater extent than Cornell voltage product by body
habitus, with a tendency to underestimate LV mass in overweight
or obese individuals.26 Our cohort was, as would be expected,
given the selection criteria for hypertension, moderately over-
weight (mean BMI 27.1), and this may, in part, account for the
lack of overlap between loci showing linkage to Cornell voltage
product and Sokolow-Lyon voltage. However, the locus on
chromosome 10 showing linkage to Sokolow-Lyon voltage may
Table 1 Characteristics of the eligible study sample
Male, n (%) 362 (43.8)
Age in years, mean (+SD) 52.4 (13.5)
Hypertension, n (%) 349 (42.3)
Antihypertensive treatment, n (%) 330 (40.0)
Systolic BP, mean in mmHg (+SD) 137 (21)
Left ventricular hypertrophy, n (%) 86 (9.9) by ECG criteriaa
283 (34.3) by echo criteriab
Weight, mean in kg (+SD) 76.8 (14.7)
Height, mean in m (+SD) 1.68 (0.1)
Body mass index, mean in kg/m2
(+SD)
27.1 (4.8)
Waist-hip-ratio (+SD) 0.87 (0.1)
Diabetes, n (%) 23 (2.8)
Table shows data on 868 individuals from 224 families with ECG available. Of
these, 826 individuals from 222 families had adequate quality echocardiographic
data available.
aECG left ventricular hypertrophy based on any one of the following criteria:
Sokolow-Lyon voltage.35 mm; RaVL .11 mm; Cornell voltage.28 mm in men
and .20 mm in women; Cornell product. 0.24 mV ms.
bEchocardiographic left ventricular hypertrophy was based on age- and
sex-specific criteria.
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for this reason be of particular interest to investigate with respect
to the development of LVH in the setting of obesity.
We found little evidence of significant linkage of echocardio-
graphic measures of LVH in this study; given the greater sensitivity
of echocardiography in detecting LVH when compared with ECG,
this initially seems paradoxical. However, an alternative expla-
nation would be that electrical and anatomical measures of
cardiac hypertrophy have separate genetic determinants, with
different genetic architecture involving several major loci for elec-
trical measures of hypertrophy,5 and no major loci for anatomical
measures of hypertrophy.16 A different genetic basis would fit with
the different underlying biology of these traits; ECG voltages
reflect the cardiomyocyte compartment, whereas anatomical
measures of LVH (such as echo LVH) encompass both cellular
and interstitial components.
Few prior studies have evaluated linkage for cardiac hypertrophy
in man.16 To the best of our knowledge, no linkage studies have
been reported on electrocardiographic measures of cardiac hyper-
trophy. Prior analyses of echocardiographic measures of LVH in
the Framingham Heart Study found a quantitative trait locus on
chromosome 22 with a LOD score of 1.57 for echocardiographic
LV mass,16 which was not replicated in the present study. Two
relatively large family studies have therefore failed to find evidence
of linkage to echo LV mass as a quantitative variable. This may be
related to the relative imprecision of echocardiographic measure-
ments. It remains to be established whether LVH measured by
cardiac magnetic resonance imaging, which measures LV mass far
more reproducibly than echocardiography, will identify genetic
signals that can be detected using linkage approaches. Even so,
some important genetic effects (relative risks of LVH of 1.5 or
thereabouts) may be too small to detect using linkage. Whole-
genome association approaches, which have higher power to
detect small effects, may identify these effects in future studies.
The electrocardiographic measures of LVH, which had a higher
heritability than the echocardiographic measures of LVH in this
study population,5 are particularly interesting for further study
because several regions of suggestive linkage were found.
We found three chromosomal regions of linkage for
electrocardiographic LVH with LOD scores. 2.0 on chromo-
somes 10, 12, and 17 (Table 2). Positional candidate genes in
these regions that are expressed in the heart include those
encoding neuregulin-3 (NRG3) and growth hormone-inducible
transmembrane protein (GHITM) on chromosome 10, keratin
hair basic 5 protein (KRTHB5), heterochromatin protein 1
(HP1), integrin alpha-5 (ITGA5), low density lipoprotein-related
protein 1 (LRP1) and ATP synthase beta polypeptide (ATP5B)
on chromosome 12, and gem-associated protein 4 (GEMIN4),
platelet-activating factor acetylhydrolase 1b alpha (PAFAH1B1),
and replication protein A1 (RPA1) on chromosome 17.
Although only moderate LOD scores (1.6–2.67) were obtained
in this study, there is precedent for the successful identification of
susceptibility genes for complex diseases under linkage peaks of
such magnitude. For example, ALOX5AP was successfully ident-
ified as a susceptibility gene for myocardial infarction (MI) and
stroke in a linkage study conducted by Helgadottir et al.27 In that
study of Icelandic families, moderate LOD scores (1.5–2.9) were
obtained for a locus that was identified for MI and stroke when
the data were divided on the basis of sex and age-of-onset.
However, none of these statistics fulfilled the stringent criteria
for genome-wide significance, which is not unusual for linkage
studies of complex disease.28 In particular, it seems highly unlikely
that the four loci with LOD scores. 1.5 that we observed for
Cornell voltage product, including one locus with an LOD score
of 2.67 and one that also showed linkage to ECG LV mass, all
arose by chance.
This study has certain limitations. A substantial proportion of the
hypertensive individuals in this study were taking antihypertensive
treatment, and there was substantial heterogeneity present both
with respect to agents and dosages. Attempting to adjust for
each of the drug classes, combinations, and dosages would likely
have been very imprecise. Accordingly, we adjusted our measure-
ments of echo and ECG LVM for BP at the time of examination, as
this to some extent took account both of the effect of hyperten-
sion on raising LV mass and the mitigating effect of concomitant
treatment. However, it remains possible that the effect of treat-
ment has tended to decrease the power of the study, and the
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Table 2 LOD scores > 1.5 for left ventricular hypertrophy variables
Phenotype Chromosomal location (cM) Flanking microsatellite marker LOD score P
ECG Sokolow-Lyon voltage
Chromosome 10 10p23.1 (106.3) D10S1686 2.21 0.0007
ECG Cornell voltage product
Chromosome 4 4q35.2 (211.9) D4S426 1.68 0.003
Chromosome 12 12q14.1 (78) D12S83 1.73 0.002
Chromosome 16 16p13.2 (7.6) D16S404 1.85 0.002
Chromosome 17 17p13.3 (6) D17S831 2.67 0.0002
ECG LV mass
Chromosome 7 7q22.1 (120) D7S515 1.67 0.003
Chromosome 12 12q14.1 (78) D12S83 2.19 0.0007
Echo left ventricular mass
Chromosome 5 5p14.1 (40.3) D5S419 1.6 0.003
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LOD scores we present may therefore be somewhat underesti-
mated. Our method should not, however, have biased our
results towards false-positive findings.
To the best of our knowledge, we report the first whole
genome analysis of electrocardiographic measures of LVH and
we provide suggestive evidence of linkage to several quantitative
trait loci. The electrocardiographic measures showed greater evi-
dence of linkage than measures for echocardiographic cardiac
hypertrophy. This study lays the basis for future association
studies and positional cloning of genes that influence electrocar-
diographic LVH, a relatively unexplored trait despite its indepen-
dent prognostic significance.
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